Table 1

Patient characteristics

All (n=180)TNBC (n=92)HR−/HER2+ (n=42)HR+/HER2− (n=46)p
Age: median (range) 54 (23–76)52 (23–76)55 (31–71)55 (31–71) 0.36
Patients, n (%)
T1
2
3
4
  2 (1)
 91 (51)
 54 (30)
 33 (18)
 2 (2)
48 (53)
27 (29)
15 (16)
 0 (0)
17 (41)
16 (38)
 9 (21)
 0 (0)
26 (56)
11 (24)
 9 (20)
 0.37
N0
1
2
3
 93 (52)
 67 (37)
 16 (9)
  4 (2)
45 (49)
35 (38)
10 (11)
 2 (2)
24 (57)
14 (33)
 3 (7)
 1 (3)
24 (52)
18 (39)
 3 (7)
 1 (2)
 0.96
StageII
III
109 (61)
 71 (39)
56 (61)
36 (39)
25 (60)
17 (40)
28 (61)
18 (39)
 0.99
Grade1
2
3
  5 (3)
 53 (29)
122 (68)
 1 (1)
 9 (10)
82 (89)
 0 (0)
 8 (19)
34 (81)
 4 (9)
36 (78)
 6 (3)
<0.001
TILLow
High
 82 (46)
 98 (54)
25 (27)
67 (73)
19 (45)
23 (55)
38 (83)
 8 (17)
 0.002
PD-1 expression in TILPositive
Negative
Unknown
 40 (22)
124 (69)
 16 (9)
26 (28)
56 (61)
10 (11)
 8 (19)
32 (76)
 2 (5)
 6 (13)
36 (78)
 4 (9)
 0.07
PD-L1 expression in tumour cellsPositive
Negative
Unknown
 62 (34)
104 (58)
 14 (8)
40 (43)
41 (45)
11 (12)
13 (31)
28 (67)
 1 (2)
 9 (20)
35 (76)
 2 (4)
 0.004
pCRPositive
Negative
 41 (23)
139 (77)
29 (32)
63 (68)
 9 (21)
33 (79)
 3 (7)
43 (93)
 0.004
p53Positive
Negative
 96 (53)
 84 (47)
58 (63)
34 (37)
26 (62)
16 (38)
12 (26)
34 (74)
<0.001
Apoptosis0
1
2
 59 (33)
 81 (45)
 40 (22)
22 (24)
51 (55)
19 (21)
 8 (19)
14 (33)
20 (48)
29 (63)
16 (35)
 1 (2)
<0.001
  • HER2, human epidermal growth factor receptor 2; HR, hormone receptors; pCR, pathological complete response; PD-1, programmed cell death-1; PD-L1,  programmed cell death-ligand 1; T, tumour; TIL, tumour-infiltrating tumour cells; TNBC, triple-negative breast cancer; N, node.